Literature DB >> 32885982

Patterns of Health Insurance Coverage and Lung Disease Progression in Adolescents and Young Adults with Cystic Fibrosis.

Dmitry Tumin1, Erin M Crowley2, Susan S Li3, William Wooten1, Clement L Ren4, Don Hayes5.   

Abstract

Rationale: Health insurance coverage has been implicated as a socioeconomic factor affecting clinical outcomes in patients with cystic fibrosis (CF), but evidence for this is mixed and varies by age.
Objectives: Focusing on adolescents and young adults with CF, we examined how multiyear patterns of health insurance coverage were associated with lung function decline and related outcomes.
Methods: We used data from the 2000 to 2015 CF Foundation Patient Registry to classify patients in three cohorts (ages 12-17 yr, adolescents; 18-23 yr, transitioning to adulthood; and 24-29 yr, young adults) according to health insurance coverage, as follows: continuous private, continuous public, intermittent public, and coverage gaps. The primary outcome was the percentage predicted forced expiratory volume in 1 second (FEV1pp), which was modeled using mixed-effects regression. Additional outcomes included outpatient visits, hospital days for pulmonary exacerbation treatment, bacterial colonization, and body mass index. Outcomes were assessed over a 6-year period (e.g., ages 12-17 yr), whereas exposures were assessed over the prior 6 years (e.g., ages 6-11 yr).
Results: The three cohorts included 3,365, 2,800, and 1,807 patients, respectively. The highest rate of FEV1pp decline was found in the middle cohort, with the annual decline being steeper among patients with continuous public (-3.1/yr; 95% confidence interval [CI], -3.3 to -2.8) or intermittent public (-2.4/yr; 95% CI, -2.6 to -2.2) coverage compared with patients with continuous private coverage (-2.1/yr; 95% CI, -2.2 to -2.0). These differences were not explained by differences in outpatient care utilization.Conclusions: During the transition to adulthood, use of public insurance was associated with accelerated lung function decline among patients with CF. The role of insurance as a causal factor in this decline or proxy for other socioeconomic characteristics should be explored in further studies.

Entities:  

Keywords:  adolescence; cystic fibrosis; health insurance

Year:  2021        PMID: 32885982     DOI: 10.1513/AnnalsATS.201911-839OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  7 in total

Review 1.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

2.  Clinical outcomes in cystic fibrosis at 6 years of age with tricare insurance coverage.

Authors:  Joseph M Collaco; Lori L Vanscoy; Kevin J Psoter; Kristin A Riekert; Kimberly M Dickinson
Journal:  J Cyst Fibros       Date:  2022-02-12       Impact factor: 5.527

3.  Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States.

Authors:  Teja Thorat; Lisa J McGarry; Krutika Jariwala-Parikh; Brendan Limone; Machaon Bonafede; Keval Chandarana; Michael W Konstan
Journal:  Pulm Ther       Date:  2021-04-28

4.  Insurance coverage and respiratory morbidities in bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Michael C Tracy; Catherine A Sheils; Jessica L Rice; Lawrence M Rhein; Leif D Nelin; Paul E Moore; Winston M Manimtim; Jonathan C Levin; Khanh Lai; Lystra P Hayden; Julie L Fierro; Eric D Austin; Stamatia Alexiou; Amit Agarwal; Natalie Villafranco; Roopa Siddaiah; Antonia P Popova; Ioana A Cristea; Christopher D Baker; Manvi Bansal; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2022-04-26

5.  Social Inequities and Cystic Fibrosis Outcomes: We Can Do Better.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Ann Am Thorac Soc       Date:  2021-02

6.  Association between insurance variability and early lung function in children with cystic fibrosis.

Authors:  Kimberly M Dickinson; Kevin J Psoter; Kristin A Riekert; Joseph M Collaco
Journal:  J Cyst Fibros       Date:  2021-06-24       Impact factor: 5.482

7.  Healthcare resource utilization and costs among children with cystic fibrosis in the United States.

Authors:  Teja Thorat; Lisa J McGarry; Machaon M Bonafede; Brendan L Limone; Jaime L Rubin; Krutika Jariwala-Parikh; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2021-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.